Bio News
U.S.-based Acadia Pharmaceuticals failed to meet the primary endpoint in a Phase 2 trial of its investigational treatment, remilifanserin, for Alzheimer’s disease psychosis.
The 60-mg group saw a 12.6-point reduction in hallucination and delusion assessment scores, but the placebo group also had a 10.4-point reduction, and the difference did not reach statistical significance.
Acadia Pharmaceuticals plans to advance the 60-mg dose into Phase 3 based on safety and efficacy signals.
Biobook Team
biobookmedia@biobook.co.krRural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
RDA develops technology to produce anti-inflammatory exosomes for pets and files patent application
HLB Submits FDA Resubmission for First-Line Liver Cancer Treatment
Celltrion Reports Third-Quarter Revenue of 1.5 Trillion Won and Operating Profit of 510 Billion Won, Up 69% Year Over Year
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
